Cytokeratin 19 Antibody (A53-B/A2.26 + BA17), Novus Biologicals™

Cytokeratin 19

Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 1-2ug/ml, Immunoprecipitation 1-2ug/500ug protein, Immunohistochemistry-Paraffin 0.5-1ug/ml, Immunohistochemistry-Frozen 0.5-1ug/ml

Monoclonal

Purified

RUO

Human

P08727

3880

Human breast cancer MCF-7 cells (A53-B/A2); Human mammary epithelial organoids (BA17)

Primary

Store at 4C.

40 kDa

A53-B/A2.26 + BA17

Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin)

Unconjugated

Mouse

Cancer, Cell Biology, Cellular Markers, Cytoskeleton Markers, Neuroscience, Stem Cell Markers

PBS with 0.05% BSA. with 0.05% Sodium Azide

CK19, CK-19, cytokeratin 19, Cytokeratin-19,40-kDa keratin intermediate filament, K19cytokeratin-19, K1CS, keratin 19, keratin, type I cytoskeletal 19, keratin, type I, 40-kd, keratin-19, MGC15366

KRT19

IgG2a κ, IgG1 κ

Protein A purified

This MAb reacts with the rod domain of human cytokeratin-19 (CK19), a polypeptide of 40kDa. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.